First-Ever Genital Herpes at 34 Weeks: What Suppressive Therapy Can and Can't Fix
A single patient, 34 weeks pregnant with her first-ever genital herpes outbreak. The disagreement isn't whether to start suppressive therapy — it's whether antiviral suppression alone can do enough to make the delivery-mode decision less urgent than it looks.
A.M., a 27-year-old first-time mother expecting a daughter she and her partner have already named, came to her routine 34-week visit with painful genital lesions she'd noticed three days earlier, assumed at first was an irritation from new laundry detergent. This is her first outbreak of anything like it in her life; type-specific HSV IgG testing sent today came back positive for HSV-2 IgG but with an equivocal IgM pattern consistent with a genuinely new, primary infection rather than a first recognized recurrence of longstanding disease — a distinction the whole rest of this conversation turns on. She's otherwise had an uncomplicated, low-risk pregnancy, and had been planning, until this morning, an unremarkable vaginal delivery.
Primary genital HSV infection late in pregnancy carries a fundamentally different, and much higher, neonatal transmission risk than recurrent disease does — published estimates for primary infection near delivery run in the range of 30 to 50 percent if the infant is exposed to the birth canal during active shedding, against roughly 3 percent or less for a recurrent outbreak, because a mother with established disease has already made and passed protective antibody to her fetus by the time she delivers, and this mother hasn't had time to. ACOG-aligned guidance recommends starting suppressive antiviral therapy now and continuing it until delivery specifically because it reduces the frequency of active lesions and asymptomatic shedding at term — but "reduces" is doing real work in that sentence, not "eliminates," and the honest question in front of the team is whether antiviral suppression changes the delivery-mode calculus meaningfully, or whether her diagnosis this close to term makes a cesarean delivery the more decisive protection regardless of how she responds to treatment. Her own timeline leaves an uncomfortably narrow margin either way: six weeks separate today from her due date, but a first labor's actual timing is never that predictable, and whatever antibody transfer might still occur before delivery depends entirely on how much of that window she actually gets, a variable nobody in the room today can control or forecast with any confidence.
Obstetric/MFM co-visit, 34 weeks
I'd start valacyclovir suppression now and plan for vaginal delivery unless she has active lesions or prodromal symptoms when labor actually starts — the standard approach we use for recurrent HSV in pregnancy. Suppression meaningfully reduces shedding and recurrence at term, and treatment will be well underway by the time she delivers.
I should say I am proposing the recurrent-disease algorithm while knowing she does not have recurrent disease, which is a position I am not entirely comfortable holding out loud.
I'd plan for scheduled cesarean regardless of her status at labor. The 30-to-50-percent transmission figure describes exactly her situation — primary infection close to term — not recurrent disease, where a mother has already passed protective antibody to the fetus. No suppression data specific to primary infection this late establish that treatment brings that risk down to something comparable to recurrent disease's roughly 3 percent.
I understand the recurrent-disease algorithm has real evidence behind it — I'm saying extending it to primary infection assumes suppression closes a gap the literature hasn't actually shown it closes, and the size of that gap is too large to extrapolate across.
I agree with the risk framing entirely — primary infection this close to term is genuinely different from recurrent disease, and I wouldn't extend the recurrent-disease algorithm here either. Where I'd land differently is on timing: her actual clinical status at labor onset, six weeks from now, is more direct evidence of her real risk at that moment than a decision made today.
Starting suppression now is not in question for either of us. I'd rather keep the delivery-mode decision open and reassess as she approaches term, with a low threshold for cesarean if any lesion or prodrome appears, than commit to a scheduled surgery six weeks in advance of the information that would actually confirm it's needed.
Agreed: valacyclovir suppression started today through delivery, and an explicit, low-threshold plan for cesarean delivery if any lesion, prodromal symptom, or uncertainty is present at labor onset — documented clearly in her chart so the decision doesn't have to be re-argued by whoever is on call when she presents in labor.
Not fully resolved: the maternal-fetal medicine specialist's underlying preference for a pre-committed cesarean remains a defensible position given the real magnitude of primary infection's transmission risk, and the group was explicit that this plan depends on genuinely low-threshold conversion being followed in practice — not on the unpredictability of who happens to be present at delivery.